Experimental products would get independent panel review for insurance coverage under California bill.
This article was originally published in The Gray Sheet
Executive SummaryCALIFORNIA EXPERIMENTAL THERAPIES BILL PROVIDES FOR INDEPENDENT REVIEW of health plan decisions to deny coverage in cases where the patient is terminally ill. The legislation, AB 1663, received final approval by the California Assembly with Senate concurrence on amendments Aug. 31, clearing the proposal for review by Gov. Pete Wilson (R). Wilson is expected to sign the measure the week of Sept. 9.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.